Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. "Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals," said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals. "We are delighted to welcome Michael to Impel's leadership team and believe that

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise. The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately. "It is my pleasure to welcome Darren to the Impel Board of Directors," said Adrian Adams, Chairman of the Board and Chief Executiv

Cowen initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $35.00

Wedbush initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $21.00

Guggenheim initiated coverage of Impel NeuroPharma with a rating of Buy and set a new price target of $32.00

3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets.

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives. As part of this process, the Company plans to consider a wide range of options with a focus on maximizing shareholder value, including a potential sale of assets of the Company, a sale of all of the Company, a merger or other strategic transactions. As the Company explores strategic options, Impel continues to provide full commercial support

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. "Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals," said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals. "We are delighted to welcome Michael to Impel's leadership team and believe that

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompan

New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered Additional Analyses from the STOP 301 Trial Show Concomitant Use of Trudhesa with Triptans and Preventative CGRP, Erenumab, Were Well-Tolerated with Limited Treatment-Emergent Adverse Events Reported SEATTLE, April 26, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today presented results from the first-ever pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of potential

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise. The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately. "It is my pleasure to welcome Darren to the Impel Board of Directors," said Adrian Adams, Chairman of the Board and Chief Executiv

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa® (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) abstracts have been selected to be presented at the upcoming American Academy of Neurology (AAN) Annual Meeting taking place in Boston, MA, April 22-27, 2023. The Trudhesa posters to be presented are as follows: A Cross-Sectional Survey of Prevailing Opinions from Headache Specialists Regarding Status Migrainosus Management; (Poster 12-001; Session 11) Presenta

Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer (CFO), Cameron Trenor, M.D., as Vice President and Head of Translational Medicine, and Anjali Kumar, Ph.D., as Vice President, Head of Business Development. In addition, Parul Doshi, M.B.A., has been promoted to Chief Data Officer in recognition of her significant contribution to the development of Cellarity and her leadership in the implementation of an efficient and scalable data infrastructure to support Cellarity's unique approach to drug creation. Cellarity is fundamentally redesignin

Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. "We continued to see strong growth in Trudhesa® prescriptions as we moved i

Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 20.9% to $0.06 during Friday's after-market session. The company's market cap stands at $13.2 million. Impel Pharmaceuticals (NASDAQ:IMPL) shares rose 11.98% to $0.27. The company's market cap stands at $6.4 million. I-MAB (NASDAQ:IMAB) shares increased by 7.19% to $1.49. The company's market cap stands at $123.1 million. Genprex (NASDAQ:GNPX) stock rose 6.63% to $0.23. The company's market cap stands at $13.3 million. Ikena Oncology (NASDAQ:IKNA) shares rose 6.59% to $2.1. The company's market cap stands at $101.3 million. Adaptimmune Therapeutics (NASDAQ:ADAP) stock increased by 6.22% to $0.48. The market value of their outstandin

Gainers Phio Pharma (NASDAQ:PHIO) shares moved upwards by 19.6% to $1.34 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 9.34% to $0.33. The market value of their outstanding shares is at $5.8 million. Aclaris Therapeutics (NASDAQ:ACRS) stock moved upwards by 8.47% to $1.07. The company's market cap stands at $75.7 million. Minerva Surgical (NASDAQ:UTRS) stock moved upwards by 8.36% to $2.85. The market value of their outstanding shares is at $25.3 million. Pasithea Therapeutics (NASDAQ:KTTA) stock rose 6.77% to $0.32. The market value of their outstanding shares is at

Shares of Workday, Inc. (NASDAQ:WDAY) surged in pre-market trading after the company reported upbeat earnings results for its third quarter. Workday posted earnings of $1.56 per share, beating market estimates of $1.41 per share. Revenue of $1.87 billion topped the analyst consensus estimate of $1.848 billion. Workday anticipated fourth-quarter subscription revenue to be $6.598 billion while adjusted operating margins were estimated to be 23.8%. Piper Sandler maintained Workday with an Overweight and raised the price target from $275 to $300. Workday shares rose 9% to $258.70 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers 180 Life Sciences Co

U.S. stocks traded lower this morning, with the Dow Jones index falling over 50 points on Monday. Following the market opening Monday, the Dow traded down 0.18% to 35,328.05 while the NASDAQ fell 0.13% to 14,231.78. The S&P 500 also fell, dropping, 0.25% to 4,548.14. Check This Out: IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying   Leading and Lagging Sectors   Communication services shares edged higher on Monday. In trading on Monday, energy shares fell by 0.7%.   Top Headline   Shopify Inc (NYSE:SHOP) merchants accomplished a record-breaking $4.1 billion in sales on Black Friday, marking a 22% increase from the previous year. Sales peaked when collective sales reach

Shares of UP Fintech Holding Limited (NASDAQ:TIGR) surged in pre-market trading after the company results for the third quarter. UP Fintech Holding posted adjusted EPADS of 10 cents up from 4 cents in the year-ago period. The company’s quarterly sales came in at $70.10 million versus, $55.41 million a year earlier. UP Fintech shares rose 7% to $5.20 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Mobiquity Technologies, Inc. (NASDAQ:MOBQ) shares rose 27.3% to $0.5728 in pre-market trading after gaining around 7% on Friday. Apollomics, Inc. (NASDAQ:APLM) shares rose 26.8% to $1.26 in pre-market trading after surging 14% on Friday. The company’s

Gainers Redhill Biopharma (NASDAQ:RDHL) shares rose 118.7% to $0.69 during Monday's pre-market session. The market value of their outstanding shares is at $7.6 million. Tharimmune (NASDAQ:THAR) stock moved upwards by 39.13% to $4.0. The market value of their outstanding shares is at $2.8 million. Apollomics (NASDAQ:APLM) stock rose 33.37% to $1.33. The company's market cap stands at $119.0 million. 60 Degrees (NASDAQ:SXTP) shares moved upwards by 23.67% to $0.7. The market value of their outstanding shares is at $4.0 million. Sunshine Biopharma (NASDAQ:SBFM) shares moved upwards by 17.58% to $0.33. The market value of their outstanding shares is at $8.4 million. Olema Pharmaceuticals (

Gainers Mira Pharmaceuticals (NASDAQ:MIRA) shares moved upwards by 9.2% to $3.59 during Friday's after-market session. The market value of their outstanding shares is at $53.0 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares moved upwards by 8.17% to $0.61. The company's market cap stands at $5.7 million. Panbela Therapeutics (NASDAQ:PBLA) shares moved upwards by 8.06% to $0.54. The market value of their outstanding shares is at $2.7 million. Estrella Immunopharma (NASDAQ:ESLA) stock rose 7.8% to $1.52. The market value of their outstanding shares is at $53.5 million. Bio-Path Hldgs (NASDAQ:BPTH) stock increased by 7.56% to $0.52. The market value of their outstanding shares is at $

Shares of FLJ Group Limited (NASDAQ:FLJ) shares jumped during Friday’s session after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology. FLJ Group shares jumped 96.4% to $0.2123 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Versus Systems Inc. (NASDAQ:VS) shares jumped 129.8% to $0.3816. Versus Systems announced a strategic investment from Cronus Equity Capital Group, LLC. BioNexus Gene Lab Corp. (NASDAQ:BGLC) jumped 78% to $0.6596. Quhuo Limited (NASDAQ:QH) gained 34% to $1.57. iRobot Corporation (NASDAQ:IRBT) gained 28.7% to $38.32. Amazon.com Inc.’s (NASDAQ:AMZN) proposed acquisition of iRobot is repor

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 50 points on Friday. The Dow traded up 0.19% to 35,339.66 while the NASDAQ fell 0.14% to 14,245.17. The S&P 500 also fell, dropping, 0.03% to 4,555.43. U.S. stock markets were closed Thursday for the Thanksgiving holiday and will also close early today. Check This Out: Visa, KeyCorp And 2 Other Stocks Insiders Are Selling   Leading and Lagging Sectors   Energy shares surged by 0.8% on Friday. In trading on Friday, communication services shares fell by 0.7%.   Top Headline   The S&P Global U.S. services PMI rose to 50.8 in November from 50.6 in the previous month, recording the highest readin